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ABSTRAK
Latar belakang: MiR-21 telah diketahui memainkan peranan dalam proliferasi dan diferensiasi osteoklas, 
tetapi peran ekspresi miR-21 dalam serum terhadap osteoporosis masih belum jelas. Penelitian sebelumnya 
menemukan bahwa ekspresi miR-21 dalam serum berkorelasi positif dengan kepadatan mineral tulang pasien 
osteoporosis pascamenopasue, tetapi faktor-faktor lain yang terlibat dalam osteoporosis pascamenopause masih 
belum diketahui. Penelitian ini bertujuan menentukan peran ekspresi miR-21 dalam serum, kadar RANKL, OPG, 
TGF-β1, sklerostin dan kalsium dalam serum, rasio RANKL/OPG dan aktivitas fisik terhadap kepadatan mineral 
tulang di tulang belakang pada wanita pascamenopause hipoestrogenik dengan osteoporosis  / postmenopausal 
women with osteoporosis (PMOP) dibandingkan tanpa osteoporosis (PMNOP) dengan titik berat pada ekspresi 
miR-21 dalam serum. Metode: penelitian ini dilaksanakan dengan desain potong lintang komparatif. Subjek 
penelitian dibagi menjadi dua kelompok, yaitu PMOP dan PMNOP. Metode kuantifikasi absolut dengan real-time 
PCR digunakan untuk menentukan kadar ekspresi miR-21 dalam serum. Hasil: nilai median ekspresi miR-21 dalam 
serum pada kelompok PMOP lebih tinggi secara bermakna dibandingkan dengan kelompok PMNOP (p=0,001). 
Ekspresi miR-21 dalam serum, RANKL, rasio RANKL/OPG dan aktivitas fisik secara bermakna berkorelasi 
dengan nilai kepadatan mineral tulang/bone mineral density (BMD) pada kelompok PMOP. Aktivitas fisik sedang 
berkorelasi negatif secara bermakna dengan ekspresi miR-21 dalam serum. Kami juga mendapatkan persamaan 
regresi linear BMD=1,373-0,085*Ln.miR-21-0,176*Log10.RANKL (R2=52,5%). Kesimpulan: Ekspresi miR-21 
dalam serum pada PMOP lebih tinggi dibandingkan dengan PMNOP. Ekspresi miR-21 dalam serum terbukti 
mempunyai efek negatif terhadap nilai kepadatan mineral tulang di tulang belakang (spinal BMD) pada wanita 
pascamenopause hipoestrogenik dengan tingkat osteoporosis sebesar 8,5%. Persamaan yang didapatkan, yaitu 
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BMD = 1,373-0,085*Ln.miR-21-0,176*Log10.RANKL  dapat menjelaskan nilai spinal BMD sebesar 52,5%.
Kata kunci: bone mineral density (BMD), osteoporosis, pascamenopause, miR-21 dalam serum.
ABSTRACT
Background: MiR-21 is known to play a role in osteoclast proliferation and differentiation, but the role of serum 
miR-21 expression in osteoporosis remains unclear. Previous research found that serum miR-21 expression was 
positively correlated with bone mineral density in postmenopausal osteoporosis patients, but other factors involved 
in postmenopausal osteoporosis still unknown. This study aimed to determine the role of serum miR-21 expression, 
concentration of RANKL, OPG, TGF-β1, sclerostin and serum calcium, RANKL/OPG ratio, and physical activity 
on bone mineral density of spine in hypoestrogenic postmenopausal women with osteoporosis (PMOP) compared 
with no osteoporosis (PMNOP), with point of interest on the expression of serum miR-21. Methods: this study was 
conducted by comparative cross-sectional design. The subjects were divided into 2 groups of PMOP and PMNOP. 
We used an absolute quantification real-time PCR method to determine serum miR-21 expressions level. Results: 
Median of serum miR-21 expression at the PMOP group was significantly higher compared to PMNOP group (p = 
0.001). Serum miR-21 expression, RANKL, RANKL/OPG ratio, and physical activity were significantly correlated 
with BMD values in the PMOP group. Moderate physical activity was significantly negatively correlated with serum 
miR-21 expression. We also obtained a linear regression equation BMD = 1.373-0.085*Ln.miR-21-0.176*Log10.
RANKL (R2 = 52.5%). Conclusion: serum miR-21 expression in PMOP was higher compared with PMNOP. Serum 
miR-21 expression proved to have a negative effect on spinal BMD values in hypoestrogenic postmenopausal 
women with osteoporosis of 8.5%. Obtained equation of BMD = 1.373-0.085*Ln.miR-21-0.176*Log10.RANKL 
can explain the value of spinal BMD by 52.5%.
Keywords: bone mineral density (BMD), osteoporosis, postmenopausal, serum miR-21.
INTRODUCTION
Osteoporosis is a systemic bone disease 
characterized by decreased bone mass and 
changes in bone tissue microarchitecture, leading 
to increased bone fragility and susceptibility to 
fracture.1 Estrogen plays an important role in bone 
loss mechanism in a postmenopausal woman. 
There are 20 to 30 percent postmenopausal 
women that are presented with osteoporosis.2-4 
Other factors involved in postmenopausal 
osteoporosis are Osteoprotegerin (OPG), 
receptor activator of nuclear factor kappa-β 
ligand (RANKL), RANKL/OPG ratio, sclerostin, 
growth factors (TGF-B, IGF-1, BMP, etc.), 
hormones (thyroid, insulin, glucocorticoid, 
parathyroid etc.), cytokines (IL-1, IL-2 and 
TNF-a), physical activity and calcium intake.5
MicroRNA (miRNA) is a short non-coding 
RNA molecule that has a function in RNA 
silencing and posttranscriptional regulation of 
gene expression.6 The present study showed that 
microRNA-21 (miR-21) plays a role in osteoblast 
proliferation and differentiation. miRNA-21 
stimulated osteoclastogenesis by increasing 
c-Fos concentration through down-regulation of 
programmed cell death 4 (PDCD4) protein and 
induction of RANKL.7 Previous study shown that 
estrogen reduces miR-21 biogenesis, therefore 
it causes osteoclast apoptosis. It has also been 
discovered that miR-21 serum was positively 
correlated with bone mineral density (BMD) in 
osteoporotic patients.8,9 However, up until now 
there has been no study on the effect of low 
estrogen levels (hypoestrogenic) with miR-21 
expression.
This study will assess the role of miR-
21 in determining bone mineral density in 
hypoestrogenic postmenopausal women 
and analyzing other factors involved in 
postmenopausal osteoporosis such as OPG, 
RANKL, RANKL/OPG ratio, sclerostin, growth 
factor (TGF-β1), serum calcium concentration, 
physical activity and body mass index, by 
excluding confounding factor such as insulin, 
thyroid hormone and use of glucocorticoid.
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METHODS
We conducted a comparative cross-sectional 
study in 120 women, comprised of 60 post-
menopausal hypoestrogenic women with 
osteoporosis (PMOP) and 60 post-menopausal 
hypoestrogenic women without osteoporosis 
(PMNOP), ages 55 to 70 years who had entered the 
postmenopausal period and had blood estradiol <30 
pg/mL. Subject were excluded when they received 
hormone replacement therapy, suffered from 
malignant or autoimmune diseases, liver disease, 
underwent routine hemodialysis, received systemic 
steroid therapy for more than 3 months, received 
bisphosphonate therapy, received anticonvulsant 
therapy, thyroid disease, diabetes mellitus, anemia 
(Hb <12 g/dl) and active smokers.
Subsequently, subjects were asked to sign an 
informed consent. Bone mineral density (BMD) 
was assessed using DXA: Medix 90, the precision 
for spine and hip was 0.6–1.5% and coefficient 
of variation was 1.5% for both. One professional 
operator with a certificate of competence in bone 
densitometry carried out BMD examination.
This study has been approved by The Ethics 
Committee of Faculty of Medicine Universitas 
Indonesia, Jakarta, Indonesia, with a reference 
number 672/UN2.F1/ETIK/2015.
Serum miR-21 Examination
Total RNA extraction was done using MirVana 
PARIS KIT (Ambion, Vilnius, Lithuania) and RNA 
concentrations were measured using NanoDropTM 
2000CC (Thermo Scientific, Pittsburgh, USA). 
cDNA synthesized using TaqMan miRNA reverse 
transcription kit and miRNA stem-loop primers 
which is for miR-21 (Applied Biosystems, Vilnius, 
Lithuania). The instrument used in cDNA synthesis 
was Veriti Therma Cycle (Applied Biosystems, 
California, USA). miR-21 amplification using 
real-time Polymerase Chain Reaction (RT-PCR) 
was done using TaqMan 2x Universal PCR Master 
Mix, No AmpErase UNG (Applied Biosystems, 
Warrington, United Kingdom) and TaqMan 
miRNA Assay (Applied Biosystems, Vilnius, 
Lithuania) consist of specific primer and probe 
for miR-21. The instrument used for RT-PCR 
was Exicycler 96 (Bioneer Corp., Daejeon, South 
Korea).
ELISA method was used to examine 
the serum concentration of sclerostin, OPG, 
RANKL, TGF-β1 dan estradiol. Total serum 
calcium examination using Arzenazo-III dye 
and we ran it in the spectrophotometer with 660 
nm wavelength. International Physical Activity 
Questionnaire was used to measure the subject’s 
physical activity.
Statistical Analysis
We used Mann-Whitney U non-parametric 
statistical test to analyze the difference of median 
value between two groups. Multiple regression 
multivariate analysis was used to assess the 
correlation between nine independent variables 
with one dependent variable. A p value of < 0.05 
was considered significant. Spearman correlation 
test was used to analyze the correlation between 
variables that were not meet a normal distribution 
criterion.
RESULTS
The clinical features of a postmenopausal 
patient with and without osteoporosis are shown 
in Table 1.
Table 1. Clinical characteristic of patient
Characteristics PMOP (n=60) PMNOP (n=60) p-Value
Age (year) 62 (67) 58.5 (65) 0.107
Weight (kg) 53.5(60) 60 (65) 0.014
Height (cm) 151.5 (155) 152.5 (155) 0.367
Menopausal period (year) 10.5 (15) 9 (15) 0.299
BMI (kg/m2) 23.38 (26.2) 24.72 (27.3) 0.083
BMD (g/m2) 0.647 (0.707) 0.867 (0.947) < 0.001
T-score (L1-4) -2.9 (-2.7) - 0.9 (-0.3) < 0.001
Estradiol (pg/mL) < 11.8 – 26.0 < 11.8 – 29.0
The value is the median (75th percentile) except estradiol only in the minimum - maximum form because estradiol value 
of less than 11.8 pg/mL is immeasurable, the p-value was measured using Mann-Whitney U test.
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Table 2. Serum MiR-21 expression and other variables in PMOP and PMNOP group
PMOP (n=60) PMNOP (n=60) p-value
Serum miR-21 expression (copies/µL x 1010) 35.30 (45.97) 24.85 (40.97) 0.006
Sclerostin (pmol/L) 26.65 (37.77) 22.8 (34.10) 0.023
TGF-β1 (pg/mL) 42571.5 (50541.50) 50706.0 (63920.0) < 0.001
RANKL (pmol/L) 198.55 (415.75) 132.95 (315.50) 0.001
OPG (pmol/L) 5.15 (6.40) 7.8 (10.12) < 0.001
RANKL/OPG ratio 41.11 (83.94) 16.81 (37.47) < 0.001
Calcium (mg/dL) 9.7 (10.20) 9.8 (10.17) 0.707
Physical Activity (score)
 - Total 2891.0 (6052.0) 3030.0 (7224.0) 0.407
PMOP : n = 60
PMNOP : n = 60
 - Walking 1366.0 (2772.0) 1378.0 (2772.0) 0.198
PMOP : n = 60
PMNOP : n = 60
 - Moderate 500.0 (1260.0) 840.0 (3360.0) 0.019
PMOP : n = 51
PMNOP : n = 50
*Value is median (75th Percentile), p-value result: Mann-Whitney U test
Table 3. Correlation of MiR-21 expression with other variables in PMOP and PMNOP groups
miR-21 Serum
PMOP (n=60) PMNOP (n=60)
r* p Value r* p Value
Sclerostin (pmol/L) -0,001 0,995 0,171 0,192
TGF- β1 (pg/mL) -0,246 0,058 -0,047 0,720
RANKL (pmol/L) 0,693 < 0,001 0,032 0,807
OPG (pmol/L) -0,021 0,876 0,052 0,692
RANKL/OPG ratio 0,661 < 0,001 0,022 0,692
Calcium (mg/dL) 0,138 0,293 0,150 0,251
Physical Activity (score)
Total 0.079 0.547 0.202 0.122
Walking 0.029 0.825 -0.182 0.165
Moderate
PMOP: n = 51 PMNOP: n = 50 -0.405 0.003 -0.453 0.001
Weight (kg) 0.163 0.213 -0.066 0.617
BMI (kg/m2) 0.138 0.293 0.023 0.862
BMD (g/m2) -0.669 < 0.001 0.231 0.078
r*: Spearman correlation test
MiR-21 Expression and Other Variables in 
Both Groups
We found out that miR-21 expression in 
a hypoestrogenic postmenopausal woman 
with osteoporosis group was higher than 
without osteoporosis, this difference was 
statistically significant with a p-value <0.05. 
Other variables that have statistically significant 
differences between the two groups are sclerotin, 
TGF-β1, RANKL, OPG, RANKL/OPG ratio and 
moderate physical activity (Table 2). We didn’t 
analyze heavy physical activity because not all 
the subject had it.
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Correlat ion Between Serum MiR-21 
Expression with Variables Measured
The correlation of serum miR-21 expression 
with other variables in PMOP and PMNOP 
groups is shown in Table 3. In the PMOP group, 
expression of miR-21 has a significantly positive 
correlation with both RANKL and RANKL/OPG 
ratio and a significantly negative correlation with 
moderate activity and BMD. In PMNOP group, 
the miR-21 expression has a negative correlation 
with moderate physical activity.
We also analyzed the correlation between 
miR-21 with other variables in the subject with a 
low estrogen level (<11.8 pg/mL) shown in Table 
4. We found that in the PMOP group with low 
estrogen level, miR-21 has a positive correlation 
with RANKL level and RANKL/OPG ratio, and 
a negative correlation with TGF-β1, OPG, and 
BMD. Both findings are statistically significant. 
On the other hand, there is no statistically 
significant correlation between the entire variable 
in PMNOP group with low-level estrogen.
Moderate physical activities have a negative 
correlation with serum miR-21 expression in both 
groups. In PMNOP group, moderate physical 
activities also have a positive correlation with 
OPG levels (r=0.404, p = 0.004) We also found out 
that, OPG levels also have a positive correlation 
with body weight (r = 0.420; p = 0.002).
In the PMOP group, serum miR-21 expression 
Table 4. Correlation of MiR-21 expression with other variables in low-level estrogen patient
miR-21 Serum
PMOP (n=40) PMNOP (n=39)
r* p Value r* p Value
Sclerostin (pmol/L) 0.032 0.844 0.133 0.421
TGF-β1 (pg/mL) -0.398 0.011 -0.109 0.508
RANKL (pmol/L) 0.618 < 0.001 0.015 0.928
OPG (pmol/L) -0.461 0.003 -0.036 0.828
RANKL/OPG ratio 0.615 < 0.001 0.015 0.927
Calcium (mg/dL) 0.079 0.629 0.098 0.555
Total Physical Activity 
(score)
0.002 0.990 0.217 0.185
Weight (kg) 0.215 0.183 0.001 0.997
BMI (kg/m2) 0.204 0.206 0.034 0.836
BMD (g/m2) -0.467 0.002 0.128 0.438
r*: Spearman correlation test
Table 5. Correlation between vertebral BMD levels with other variables
BMD (L1-L4)
PMOP PMNOP
r* p Value r* p Value
Serum miR-21 expression (copies/
µL x 1010) -0.669 < 0.001 0.231 0.078
Sclerostin (pmol/L) 0.086 0.516 0.038 0.776
TGF-β1 (pg/mL) -0.083 0.531 -0.085 0.521
RANKL (pmol/L) -0.726 < 0.001 -0.063 0.633
OPG (pmol/L) 0.241 0.065 0.144 0.274
RANKL/OPG Ratio -0.723 < 0.001 -0.078 0.553
Calcium (mg/dL) 0.023 0.861 0.151 0.251
Total physical activity (score) 0.326 0.011 -0.091 0.495
IMT (kg/m2) -0.096 0.467 -0.061 0.643
r*: Spearman correlation test
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has a positive correlation with RANKL levels 
and RANKL/OPG ratio, and it has a negative 
correlation with OPG and TGF-β1. OPG level 
is positively correlated with TGF-β1 level (r = 
0.449, p = 0.004). In PMNOP group, OPG level 
has a significantly negative correlation with 
RANKL/OPG ratio (r = -0.533, p= <0.001).
Correlation Between BMD with Other 
Variables
Correlation between BMD lumbar (L1-L4) 
as a dependent variable with other variables 
measured are shown in Table 5. In PMOP group 
BMD has a negative correlation with serum miR-
21 expression, RANKL level, and RANKL/OPG 
ratio, and has a positive correlation with total 
physical activity. On the other hand, there is no 
significant correlation between BMD with other 
variables in PMNOP group.
Multiple Linear Regression Analysis of MiR-
21 with Bone Mineral Density
In order to see the role of miR-21 to 
vertebral BMD, we did a multiple multivariate 
linear regression analysis with vertebral BMD 
as a dependent variable and serum miR-21 
expression, RANKL, OPG, and total physical 
activity as independent variables. By using a 
backward stepwise method, we acquired linear 
regression equation for BMD based on serum 
miR-21 expression levels and RANKL levels, 
BMD = 1.373 – 0.085 x Ln. miR-21 – 0.176 x 
Log10RANKL, (R2= 52.5%).
We tried to find the cutoff point of serum 
miR-21 expression between PMOP and PMNOP 
group, in order to make basic data that will be 
useable to develop further research in the future. 
Based on that data, we acquired the cutoff point 
for miR-21 in both groups is 30.1-copies/µL x 
1010. Based on this cutoff point, we found that 
there are 42 patients (72%) in PMOP group and 
19 patients (31%) in PMNOP group who had a 
higher result of cutoff point miR-21 expression.
DISCUSSION
This study revealed that serum miR-21 
expression in the PMOP group is significantly 
higher than PMNOP group. It also significantly 
negatively correlated with vertebral BMD. Sun 
et al.10 also discovered an up-regulation of miR-
21 expression in postmenopausal osteoporotic 
patients than without osteoporosis. Lian et al.11 
also discovered an increase of serum miR-21 
expression in 15 postmenopausal women with 
pelvic fracture than 12 post-menopausal women 
with severe osteoarthritis which need a prosthetic 
implant. However, Sugatani et al.12-13 should 
a positive correlation of miR-21 expression 
with vertebral BMD value. Yavropoulo et al.14 
also found lower expression of serum miR-21 
expression in 35 postmenopausal women with 
low BMD levels accompanies with at least 
one vertebral fracture than 35 low BMD levels 
postmenopausal woman without any vertebral 
fracture.15-17 These different outcomes compared 
to our study can be due to the different number 
of patient involvement in the study. In addition, 
this study also did not measure the estrogen level 
of the study subject.
Serum miR-21 has a positive correlation 
with RANKL levels, this indicates that miR-21 
overexpression led to an increase in RANKL 
levels which will affect bone mineral density. 
Serum miR-21 expression has a negative 
correlation with OPG level. High expression 
of miR-21 will cause a decrease in OPG 
concentration. This is similar to a study done 
by Pitari et al.19, up-regulation of miR-21 will 
cause down-regulation of OPG. In PMOP 
group, OPG level is lower than PMNOP group. 
Osteoprotegerin (OPG) act as a decoy in RANK-
RANKL signal which will inhibit the formation 
and suppress the life span of the osteoclast.19-21 
In this study, the RANKL/OPG ratio in 
the PMOP group is higher than PMNOP and 
statistically significant. This is similar to a study 
conducted by Xu et al.22, which also found an 
increase of RANKL/OPG ratio in the PMOP 
group. High RANKL/OPG ratio will also 
increase the number of osteoclasts and resorptive 
activity of the bone. In addition to miR-21, we 
found out that serum miR-21 expression has a 
positive correlation with the RANKL/OPG ratio. 
This also indicates that overexpression of miR-21 
will lead to an increase of RANKL/OPG ratio 
which later will a decrease of BMD.
Serum TGF-β1 levels are statistically 
significantly lowered in the PMOP group. 
Several previous studies reported that TGF-β1 
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has a protective role against osteoporosis and 
assist bone recovery. Wu and colleagues found 
that TGF-β1 levels in postmenopausal women 
are lower than premenopausal women.22 TGF-β1 
regulates osteoblast and osteoclast differentiation, 
producing a balance in bone formation and 
resorption.23 We discovered that serum miR-21 
expression has a negative correlation with the 
TGF-β1 level in PMOP group. Overexpression 
of serum miR-21 will decrease serum TGF-β1 
concentration.
Figure 1. Proposed mechanism of miR-21 role on bone 
mineral density in hypoestrogenic postmenopausal women 
with osteoporosis.
We also measure physical activity score 
between the two groups. We found that moderate 
physical activity has a negative correlation with 
serum miR-21 expression and have a positive 
correlation with OPG levels in both groups. 
These suggest that moderate physical activity 
can suppress miR-21 expression and promote 
OPG production that will lead to reduce of bone 
resorption and normalize BMD.
Based on the above result, we proposed 
a mechanism scheme of miR-21 role with 
bone mineral density in hypoestrogenic 
postmenopausal women with osteoporosis. 
Low estrogen levels in postmenopausal women 
cause an increase of serum miR-21 expression. 
High expression of mir-21 increases RANKL 
production and decreases OPG and TGF-β1 
levels. Increasing of RANKL levels followed by 
the reduction of OPG levels led to an increase of 
RANKL/OPG ratio. All of that will eventually 
increase bone resorption and reduce BMD, 
causing osteoporosis. Moderate physical activity 
inhibits serum miR-21 expression; this lower the 
effect of miR-21 expression to BMD compare to 
RANKL. (Figure 1)
We acquired a linear progression formula 
BMD = 1,373 -0,085*Ln.miR-21 - 0,176*Log 
10.RANKL. Based on the formula, every unit 
of miR-21 expression will decrease BMD for 
about 8.5%. Meanwhile, RANKL will decrease 
BD for about 17.6%. The formula able to predict 
the BMD value for 52.5% (R2 = 52.5%). This 
finding may able to allow a potential combined 
therapy of miR-21 and RANKL in Osteoporosis. 
We also measured other variables such as 
sclerostin and calcium levels. We found that 
sclerostin levels are higher in the PMOP group 
than PMNOP. Calcium levels are higher in 
PMNOP group than PMOP. Both variables don’t 
have a significant correlation with serum miR-21 
expression.
This study has several limitations. The 
first limitation is we did not measure other 
parameters that also play an important role in bone 
remodeling, which may affect BMD values such as 
IL-1, IL-6, TNF-α, and nutritional intake. Another 
limitation, we did not perform serum miR-21 
test in subjects who are still in menstrual age or 
premenopausal so that the term of overexpression 
cannot be determined. The last limitation, it is still 
unknown whether the association between miR-
21 expression and BMD values also reflects bone 
metabolic activity because we did not evaluate 
bone resorption and bone formation markers.
CONCLUSION
Serum miR-21 expression in hypoestrogenic 
postmenopausal women with osteoporosis 
has a higher expression compared with no 
osteoporosis. Serum miR-21 expression proved 
to have a negative effect on spinal BMD values 
in hypoestrogenic postmenopausal women with 
osteoporosis of 8.5%, with linear regression 
equation BMD=1.373-0.085*Ln.miR-21-
0.176*Log10.RANKL. This equation can 
explain the value of spinal BMD by 52.5%.
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